Aa
A
A
Close
Avatar_universal
Gilead GS9620 Prediction
I am making a prediction that this drug will be released by Gilead in 2017/2018.

Why?  Gilead loses the patent on Viread in 2017/2018.  Their cash cow will have run its course and they will be more than happy to release this drug to continue to reap the money for HBV treatment.  

There is one thing I remember Dr. Gish telling me that I won't forget.  He said "you know Gilead is working on a drug that will make it so you don't have to take Viread for ever.  It's kind of odd that they'd be working on a drug that will eliminate their Viread income".  

Not really.  If they release it when Viread loses patent, it's a win-win for them!
Cancel
7 Answers
Page 1 of 1
Avatar_universal
"I am making a prediction that this drug will be released by Gilead in 2017/2018. "

Provided that GS9620 shows the expected efficacy on hbvers (and hcvers).
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
They've already done small cohort human trials, and the drug works and is well tolerated.  
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
Really?  They already have a small amount of data on hbvers (human), not just healthy volunteers?  Were they cured?  If so, that would be truly exciting.
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal

i do hope myrcludex and replicor are able to fasten this process or imiquimod itself show some effect, this is the only thing to make them move very fast

Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
So,
Now, we have three horses running in the course: rep9ac(replicor), mycrludex and GS9620 ..

Good ,, i hope number of horses will increase ..
at least one of them reach to the finalist soooon ..
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
Actually there are 4, if you include the sRNAi from Arrowhead Research.
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
Had appt with Gish - he said there is unreleased data from clinical trials showing GS 9620 has been effective, and non-toxic in escalating doses.  He also said clinical trials are still ongoing and they've relaxed the inclusion criteria, so others may be able to join (veteranB).
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Your Answer
Avatar_universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Gilead GS9620 Prediction
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
233488_tn?1310696703
Blank
Marathon Running Done Over Many Yea...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
233488_tn?1310696703
Blank
New Article on Multifocal IOL vs &q...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
748543_tn?1443740527
Blank
TMJ/TMJ The Connection Between Teet...
01/15 by Hamidreza Nassery , DMD, FICOI, FAGD, FICCMOBlank
Top Hepatitis Answerers
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
Jatashankar
India
Avatar_m_tn
Blank
sorte
Poland
Avatar_m_tn
Blank
luckyman316
Avatar_m_tn
Blank
Aduiski
Other